Measurable Residual Disease - What does it mean to be MRD Positive

Measurable Residual Disease - What does it mean to be MRD Positive

cancergrace

5 months
158 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
GRACE - Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel consisted of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of Hematology and Blood and Marrow Transplantation at the University of California, San Francisco). In this video, the doctors discuss what it means to be MRD positive. For more information visit GRACE at https://cancerGRACE.org, or CCO at https://www.clinicaloptions.com/oncol....
Up Next Autoplay
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Category: General
2 Views
Mount Sinai Health System 1 week
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Category: General
20 Views
Cancer-News 1 month
Interesting Data Presented at WCLC 2019
Interesting Data Presented at WCLC 2019
Category: General
13 Views
Cancer-News 2 months
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Category: General
20 Views
Cancer-News 2 months
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global acquires new anticancer drug platform from University of Texas
Category: General
12 Views
Cancer-News 2 months
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Category: General
118 Views
Annual-Meeting 5 months
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Category: General
26 Views
Annual-Meeting 5 months
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Category: General
48 Views
Annual-Meeting 5 months
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Category: General
76 Views
Annual-Meeting 5 months
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
Category: General
301 Views
Annual-Meeting 5 months